Aeglea Biotherapeutics Stock News

AUSTIN, Texas , Jan. 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peop

At least one of the three could be in store for better news in the future.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Director Armen Shanafelt bought 121,799 shares of the stock in a transaction dated Thursday, December 9th. The shares were acquired at an average cost of $3.67 per share, for a total transaction of $447,002.33. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through []

Related Stocks: AGLE ,

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) CEO Anthony G. Quinn bought 43,108 shares of the firm’s stock in a transaction dated Thursday, December 9th. The shares were acquired at an average cost of $3.70 per share, with a total value of $159,499.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is […]

Aeglea BioTherapeutics (NASDAQ:AGLE) had its price target cut by Piper Sandler from $12.00 to $9.00 in a research report sent to investors on Monday, The Fly reports. They currently have an overweight rating on the biotechnology companys stock. Several other research firms have also weighed in on AGLE. Zacks Investment Research lowered Aeglea BioTherapeutics from []

Aeglea achieved primary endpoint in reducing arginine levels with its drug pegzilarginase for ARG1-D, which in turn reduced ammonia in the blood plasma, by an average of 80%. BLA filing of pegzilargin

MIxed phase 3 clinical trial results are making investors nervous.

AUSTIN, Texas, Dec. 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the pivotal Phase 3 study,

AUSTIN, Texas, Dec. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative s

Brokerages expect Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) to post ($0.29) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Aeglea BioTherapeutics earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.34). Aeglea BioTherapeutics reported earnings per share of []

Renaissance Technologies LLC grew its position in shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) by 383.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,787 shares of the biotechnology companys stock after purchasing an additional 40,287 shares during the period. Renaissance Technologies LLC owned []

Analysts expect that Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) will announce sales of $3.07 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Aeglea BioTherapeutics earnings, with estimates ranging from $1.40 million to $6.41 million. The company is scheduled to issue its next earnings results on Thursday, March 17th. On []

Analysts predict that Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) will report earnings of ($0.29) per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Aeglea BioTherapeutics earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.34). Aeglea BioTherapeutics reported earnings of ($0.34) []

Analysts expect Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) to post earnings of ($0.29) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Aeglea BioTherapeutics earnings, with estimates ranging from ($0.34) to ($0.20). Aeglea BioTherapeutics posted earnings of ($0.34) per share during the same quarter last year, which would suggest []